Thomasville National Bank Boosts Holdings in Sanofi (NASDAQ:SNY)

Thomasville National Bank increased its holdings in Sanofi (NASDAQ:SNY) by 1.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,101 shares of the company’s stock after purchasing an additional 1,265 shares during the period. Thomasville National Bank’s holdings in Sanofi were worth $3,863,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Barrow Hanley Mewhinney & Strauss LLC raised its holdings in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the last quarter. Natixis Advisors LLC increased its position in shares of Sanofi by 4.1% during the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after purchasing an additional 114,133 shares during the last quarter. Finally, Raymond James & Associates increased its position in shares of Sanofi by 4.8% during the 3rd quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock valued at $162,479,000 after purchasing an additional 129,472 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Down 0.3 %

Shares of SNY stock traded down $0.17 during mid-day trading on Monday, hitting $48.56. The stock had a trading volume of 829,948 shares, compared to its average volume of 2,143,126. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The firm has a market capitalization of $123.24 billion, a P/E ratio of 24.78, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57. The firm’s 50-day moving average is $48.70 and its two-hundred day moving average is $52.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the business earned $2.55 EPS. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, analysts predict that Sanofi will post 4.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and an average target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.